Clinical Study
The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes
Table 1
Changes of metabolic profiles and bone turnover markers after pioglitazone treatment.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data are mean ± SD. ; , compared to before therapy. FBG: fasting blood glucose; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; T-CHO: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; BAP: bone-specific alkaline phosphatase; P1NP: procollagen type 1 N-terminal propeptide; OC: osteocalcin; CTX: C-terminal telopeptide of type 1 collagen. |